ALB and neoplasm: Last but not the least, in preclinical studies, compared to other peer TriTACs, HPN424 [66] and HPN536 [121], which are configured in a tandem domain format of anti-CD3-anti-albumin-anti-tumor target configuration (also known as the C:A:T format), HPN328 is configured in an anti-tumor target-anti-albumin-anti-CD3 configuration (T:A:C format) [122].